Drugs, Generic

• 

  Subject Areas on Research

  • A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation. 
  • A randomized, prospective double-blind comparison of the efficacy of generic propofol (sulphite additive) with diprivan. 
  • ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. 
  • Aerosolized ribavirin: the most expensive drug for pneumonia. 
  • Assessing bioequivalence and drug interchangeability. 
  • Authors' Reply to Courtney Suggs and Colleagues' Comment on: "Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs". 
  • Bioequivalence review for drug interchangeability. 
  • Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs. 
  • Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications. 
  • Buprenorphine treatment: factors and first-hand experiences for providers to consider. 
  • Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs. 
  • Comparison of Outcomes Following a Switch From a Brand to an Authorized Versus Independent Generic Drug. 
  • Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). 
  • Does generic entry always increase consumer welfare? 
  • Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act. 
  • Frequency estimator for assessing of follow-on biologics. 
  • Generic and branded drugs for the treatment of people living with HIV/AIDS. 
  • Generic clopidogrel: time to substitute? 
  • Global health and university patents. 
  • Haloperidol for postoperative nausea and vomiting: are we reinventing the wheel? 
  • Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report. 
  • Hospital pharmacy decisions, cost containment, and the use of cost-effectiveness analysis. 
  • Improving Medication Adherence in Cardiometabolic Disease: Practical and Regulatory Implications. 
  • Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS). 
  • Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs. 
  • NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. 
  • On assessing bioequivalence and interchangeability between generics based on indirect comparisons. 
  • On safety margin for drug interchangeability. 
  • Options to Promote Competitive Generics Markets in the United States. 
  • Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry. 
  • Protect pharmaceutical innovation. 
  • Provider and patient drivers of ototopical antibiotic prescription variability. 
  • Rocephin--the thin end of the wedge. 
  • Should Physicians be Encouraged to use Generic Names and to Prescribe Generic Drugs? 
  • Some thoughts on drug interchangeability. 
  • Statistical and regulatory considerations in assessments of interchangeability of biological drug products. 
  • Statistical evaluation of the scaled criterion for drug interchangeability. 
  • The bootstrap procedure in individual bioequivalence. 
  • The impact of evidence-based education on prescribing in a psychiatry residency. 
  • The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC study. 
  • The impact of manufacturer coupon use in the statin market. 
  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. 
  • The state and consequences of dermatology drug prices in the United States. 
  • Understanding therapeutic equivalence in epilepsy. 
  • Use of Therapeutic Drug Monitoring, Electronic Health Record Data, and Pharmacokinetic Modeling to Determine the Therapeutic Index of Phenytoin and Lamotrigine.